Preclinical studies of Flonoltinib Maleate, a novel JAK2/FLT3 inhibitor, in treatment of JAK2V617F-induced myeloproliferative neoplasms (Vol 12, 37, 2022)

被引：0
|
作者：
Hu, Mengshi
Yang, Tao
Yang, Linyu
Niu, Lu
Zhu, Jinbing
Zhao, Ailin
Shi, Mingsong
Yuan, Xue
Tang, Minghai
Yang, Jianhong
Pei, Heying
Yang, Zhuang
Chen, Qiang
Ye, Haoyu
Niu, Ting
Chen, Lijuan
机构：
[1] West China Hospital of Sichuan University,State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics
[2] West China Hospital of Sichuan University,Department of Hematology and Research Laboratory of Hematology
[3] Chengdu Zenitar Biomedical Technology Co.,undefined
[4] Ltd,undefined
来源：
BLOOD CANCER JOURNAL | 2024年 / 14卷 / 01期
关键词：
D O I：
10.1038/s41408-024-01058-y
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [41] Effects of CYT387, a Potent Novel JAK2 Inhibitor on JAK2-V617F Induced MPD
    Bumm, Thomas G. P.
    Tyner, Jeffrey W.
    Deininger, Jutta
    Loriaux, Marc
    VanDyke, Jonathan
    Druker, Brian J.
    Burns, Christopher J.
    Fantino, Emmanuelle
    Deininger, Michael W. N.
    BLOOD, 2008, 112 (11) : 316 - 317
  • [42] JAK2V617F allele burden, JAK2 46/1 haplotype and clinical features of Chinese with myeloproliferative neoplasms
    Wang, J.
    Xu, Z.
    Liu, L.
    Gale, R. P.
    Cross, N. C. P.
    Jones, A. V.
    Qin, T.
    Ai, X.
    Xu, J.
    Zhang, T.
    Sun, X.
    Li, Q.
    Zhang, P.
    Zhang, Y.
    Xiao, Z.
    LEUKEMIA, 2013, 27 (08) : 1763 - 1767
  • [43] FREQUENCY OF JAK2 EXON 12 MUTATIONS IN JAK2 (V617F) NEGATIVE PATIENTS WITH CHRONIC MYELOPROLIFERATIVE DISORDERS (CMD)
    Bernardi, M.
    Ruggeri, M.
    Albiero, E.
    Madeo, D.
    Rodeghiero, F.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 294 - 294
  • [44] JAK2V617F allele burden, JAK2 46/1 haplotype and clinical features of Chinese with myeloproliferative neoplasms
    J Wang
    Z Xu
    L Liu
    R P Gale
    N C P Cross
    A V Jones
    T Qin
    X Ai
    J Xu
    T Zhang
    X Sun
    Q Li
    P Zhang
    Y Zhang
    Z Xiao
    Leukemia, 2013, 27 : 1763 - 1767
  • [45] MPL mutation effect on JAK2 46/1 haplotype frequency in JAK2V617F-negative myeloproliferative neoplasms
    M M Patnaik
    T L Lasho
    C M Finke
    N Gangat
    D Caramazza
    S Siragusa
    C A Hanson
    A Pardanani
    A Tefferi
    Leukemia, 2010, 24 : 859 - 860
  • [46] MPL mutation effect on JAK2 46/1 haplotype frequency in JAK2V617F-negative myeloproliferative neoplasms
    Patnaik, M. M.
    Lasho, T. L.
    Finke, C. M.
    Gangat, N.
    Caramazza, D.
    Siragusa, S.
    Hanson, C. A.
    Pardanani, A.
    Tefferi, A.
    LEUKEMIA, 2010, 24 (04) : 859 - 860
  • [47] Angiogenesis in JAK2 V617F positive myeloproliferative neoplasms and ruxolitinib decrease VEGF, HIF-1 enesis in JAK2 V617F positive cells
    Cheng, Zhiyong
    Fu, Jianzhu
    Liu, Guimin
    Zhang, Lijun
    Xu, Qian
    Wang, Su-yun
    LEUKEMIA & LYMPHOMA, 2018, 59 (01) : 196 - 203
  • [48] THE C618R MUTATION OF JAK2 POTENTIATES THE JAK2V617F-INDUCED PHOSPHORYLATION AND ACTIVATION OF DOWNSTREAM TARGETS
    Vaz, A.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 399 - 399
  • [49] JAK2-V617F Mutation in Patients with Myeloproliferative Neoplasms: Association with FLT3-ITD Mutation
    Spasovski, Vesna
    Tosic, Natasa
    Kostic, Tatjana
    Pavlovic, Sonja
    Colovic, Milica
    SRPSKI ARHIV ZA CELOKUPNO LEKARSTVO, 2010, 138 (9-10) : 614 - 618
  • [50] JAK out of the box: myeloproliferative neoplasms-associated JAK2 V617F mutations contribute to aortic aneurysms
    Elf, Shannon E.
    HAEMATOLOGICA, 2021, 106 (07) : 1783 - 1784
12345